Norethynodrel

Summary

Norethynodrel (CHEMBL1387) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 298.4 Da · C20H26O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1387
Name	Norethynodrel
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6231
Molecular formula	C20H26O2
Molecular weight	298.4
InChIKey	ICTXHFFSOAJUMG-SLHNCBLASA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3CCC(=O)C4

IUPAC name: (8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one

Also known as: Enidrel, Norethynodrel, Norethynodrel component of enovid, Noretinodrel, Noretynodrel, NSC-15432, SC-4642, SID11533052, SID26748167, NORETHYNODREL, SID144203910, noretynodrel

Patent coverage: 1,891 distinct patent families (6,965 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: Microtubule-associated protein tau, Survival motor neuron protein, Androgen receptor, Estrogen receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 18 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	7.6	AC50	25.1	nM	CHEMBL_ACT_25204209
AR	7.52	AC50	30	nM	CHEMBL_ACT_25203276
ESR1	6.99	AC50	103.2	nM	CHEMBL_ACT_25138776
SLC6A4	6.74	AC50	182.3	nM	CHEMBL_ACT_25151245
P15207	5.81	IC50	1549	nM	CHEMBL_ACT_1605630
SMN1	5.75	Potency	1778	nM	CHEMBL_ACT_3888625
CHRM1	5.56	AC50	2760	nM	CHEMBL_ACT_25210143
ADORA3	5	AC50	10070	nM	CHEMBL_ACT_25198653

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).